To traders looking for help; I've found the most
remarkable service to help me trade in the stock market the
right way! I've traded so much more effectively &
profitably since I found http://www.pcmoneyclub.com If this
sounds like a promo, so what! I want to let everyone
know about them.
I lost a lot of money trading
from the message boards and surfing the net for free
trading advise. Finally, I realized that's not smart
trading! Since I've joined PcMoneyClub.com, I now practice
their trading philosophy, "put your money where it
moves!" To say they're impressive is an understatement. I
would've never believed that a service like this could
outline detailed positions, entries & exits, in specific
stocks so accurately. Their calls have been unbelievably
accurate on both the long and short sides. I would have
never been able to trade this profitably
This site has it all! The best trading systems,
strategies, training, detailed position coaching daily, and
their technical charting and other tools are fantastic.
You owe it to yourself to check out PcMoneyClub.com.
NO, I don't work for the firm, I just like them a
It's more fun when you win! I just
finished my best week ever in the stock market, and I have
confidence for next week!
The average Radiation doseage is delivered (Beta)
in 5 to 15 minutes. The current trails require a
Radiation Oncologist to be present. These systems will
prove safe and fool proof. The computer figures the
dose and Radiated source half-life to deliver the
perfect exposure.Look for Radiation Oncologist to be out
of the picture by final FDA appproval.Studies being
conducted on de novo lession and restenosed stents.
I have seen all that stuff, but I have also heard
the initial data has, so far, been VERY difficult to
reproduce. My questions are:
1) I do not believe that
radiologists are certified to introduce both beta and gamma
and therefore the proceedure will require a rad/onc
MD in every case. What is the chance of that
happening? 2) Who are the candidates? DeNovo's, 1st
restenosis, SVG's, LIMA/RIMA's, in-stent restenosis?, and
3) From what I have read, these cases are very time
consuming; when a stent can be done in 1 hour, skin to skin,
is there going to be a market for a 3-4 hour
proceedure that reduces restenosis from the high 20's to the
Sorry, my mistake, I thought I had read that info
some time back. Thanks for the info, I have lots of
questions re:iv radiation primarily due to a family friend
being a radiation oncologist. I appreciate your input.
Been in Int. Card. through out the 90's and AVE
salesforce is as good as any. Ultimately it is the product
and its attributes that will determine marketshare,
usage patterns, etc.BSX will try to shift focus away
from a me too, older generation stent and on to things
such as "socs", delivery system, etc. Will it work? In
some cases yes, but the best stent technology will
likely prevail just as it has in other parts of the
world. There will have to be something about Nir that is
clearly superior to gfx or Multilink for it to knock
those two out of labs. Based on the specs and data, I'm
not sure what that might be.
about (from the exposure I've had to) the AVE
the similarities to another California
Oakland Raiders. There seem to be a
number of AVE
field sales people that have failed or
been terminated from
other medical device
companies. I am confidant there were
visionaries that joined the company 12-18
however, there seem to be a number of 'salary
tragedies' that were brought in to fill the roster.
How is the Fonz?
You made the challenge, we choose the time and
place. Time; 1998, 1999, & 2000. Place; All domestic and
foreign markets. BTW, SciMed is just one division, you
have all of BSX to contend with. You may be the
toughest guys on your own block but now you're playing
with the the big people. Do you feel lucky?
With the historical trading pattern of
BSX,especially the huge trough earlier in the year,and a pe at
60,i was examining this one as a short candidate.Do
you longs really think this company will make it
through sept/oct crash intact as a result of good
earnings or will a lousy market bring this baby back to
Watch out for Novoste in the U.S. Guidant may
have the stronger patent position. They purchased
NeoCardia and Nucletron to give themselves, not only a good
product entry for radiation, but arguably the strongest
patent position in the U.S.
There may also be
market challenges with radiation, such as, the
cardiologist can't do the procedure alone. Current regulations
require that a doc whose licensed to handle radiation be
present during the procedure, like a radiologist. This
will be expensive and complicate scheduling, etc.
There will also be potentially major logistical issues
for companies not used to handling radioative
You guys are right, though, it has gotten
the biggest hype and potentially some impressive
results in trials. My question is, what will restenosis
rates be 6-12 months after a stent procedure in
1999/2000 when newer stents are out compared to radiation
results? How good is good enough?